476 related articles for article (PubMed ID: 27600258)
1. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
Li M; Yin J; Mao N; Pan L
Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
[TBL] [Abstract][Full Text] [Related]
3. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
4. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
7. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
8. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
10. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Jakobsen A
Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
[TBL] [Abstract][Full Text] [Related]
11. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract][Full Text] [Related]
12. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
14. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
15. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
16. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
17. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
Yan H; Qiu L; Xie X; Yang H; Liu Y; Lin X; Huang H
Oncol Rep; 2017 Mar; 37(3):1412-1418. PubMed ID: 28184931
[TBL] [Abstract][Full Text] [Related]
18. Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer.
Innamaa A; Jackson L; Asher V; van Schalkwyk G; Warren A; Keightley A; Hay D; Bali A; Sowter H; Khan R
Clin Transl Oncol; 2013 Nov; 15(11):910-8. PubMed ID: 23479219
[TBL] [Abstract][Full Text] [Related]
19. Sterol regulatory element-binding protein 1 is required for ovarian tumor growth.
Nie LY; Lu QT; Li WH; Yang N; Dongol S; Zhang X; Jiang J
Oncol Rep; 2013 Sep; 30(3):1346-54. PubMed ID: 23818099
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
